Stay updated on KarXT Long-Term Safety in Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the KarXT Long-Term Safety in Schizophrenia Clinical Trial page.

Latest updates to the KarXT Long-Term Safety in Schizophrenia Clinical Trial page
- Check3 days agoChange DetectedThe study record now includes related topics tags for Schizophrenia and MedlinePlus Genetics. These tags connect the trial to broader educational resources about the condition and genetics, helping with discoverability.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page footer was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating an interface or release version change without modifying the study information.SummaryDifference0.0%

- Check25 days agoChange DetectedAdded Revision: v3.5.2; removed Schizophrenia, related topics: MedlinePlus Genetics, and Revision: v3.5.0.SummaryDifference0.2%

- Check32 days agoChange DetectedRelated topics Schizophrenia and MedlinePlus Genetics were added to the study page to provide broader context and improve discoverability.SummaryDifference0.1%

- Check40 days agoChange DetectedRemoved the Schizophrenia topic tag and related topics including MedlinePlus Genetics from the page; this affects navigation tags but does not alter the core trial content.SummaryDifference0.1%

- Check47 days agoChange DetectedSponsor information was updated to include Karuna Therapeutics, Inc., a Bristol Myers Squibb company, and schizophrenia- and MedlinePlus Genetics-related topics were added. The standalone term Karuna Therapeutics was removed.SummaryDifference0.3%

Stay in the know with updates to KarXT Long-Term Safety in Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT Long-Term Safety in Schizophrenia Clinical Trial page.